Greater Bay Area start-ups optimistic about revenue growth, according to observers, survey by HKTDC and HSBC
- Survey polls 308 firms from sectors such as new economy, information technology and hardware, and biotechnology
- Biotech start-ups were the most optimistic, with about 30 per cent expecting their revenue to double in the next three years
The joint survey by HKTDC and HSBC, which polled the founders of 308 firms from sectors such as new economy, information technology and hardware, and biotechnology, was conducted by HKTDC between August and September.
10:01
Hong Kong can't miss Greater Bay Area boat in post-Covid-19 recovery, Victor Fung of Fung Group says
Biotechnology start-ups were the most optimistic, with about 30 per cent of respondents expecting their revenue to double in the next three years, according to the survey. It found that 71 per cent of respondents expected their revenue to grow more than 25 per cent in the next three years, with 18 per cent estimating that their revenue would more than double in the same period.
“The potential for developments in biotechnology to improve health care are more widely appreciated due to the pandemic, thus creating new opportunities for biotech start-ups,” Kwan said. “In addition, government and private funding are also paying more attention to biotech start-ups.”
Phase Scientific, a Hong Kong-based biotechnology start-up producing medical diagnostic products, had sold millions of Covid-19 tests globally during the pandemic and was already benefiting from these factors.
“We are very confident,” Ricky Chiu Yin-to, its chairman, said, adding that he had high hopes as far as the company’s revenue growth was concerned.
The survey also found that more than 80 per cent of respondents will use Hong Kong’s services in the next three years, with banking being the most sought-after service. The city would serve as a platform for bay area companies looking to raise funds and expand overseas, Kwan said.
02:35
China's ambitious plan to develop it own ‘Greater Bay Area’
The city’s financial expertise was an advantage when it came to developing hi-tech industries, such as biotechnology, as it allowed companies to access much-needed funding for their development, said Phase Scientific’s Chiu. “I absolutely agree that Hong Kong is the right place [for fundraising], and it will continue to be a good place to do that,” he added.